Plant-Based Vaccines: Designing Antigens, Enhancing Diversity, and Optimizing

Louis Erin^*
*Correspondence: Louis Erin, Department of Biology, Cochin University of Science & Technology, Cochin, India, Email:

Introduction

Plant-based vaccines have emerged as a promising alternative to traditional vaccine production methods, leveraging the advantages of plant expression systems for antigen design, diversity, and large-scale production. Unlike conventional vaccines produced in microbial, insect, or mammalian cell cultures, plant-based systems offer scalability, cost-effectiveness, and enhanced safety due to their inability to harbor human pathogens. The use of genetically modified plants for vaccine production has led to innovative approaches in antigen engineering, allowing for the development of highly immunogenic and stable vaccine candidates. Antigen design is a crucial aspect of plant-based vaccine development, as the effectiveness of the vaccine depends on the ability of the expressed antigen to elicit a strong and protective immune response. Various strategies have been employed to optimize antigen expression in plants, including codon optimization, fusion to carrier proteins, and targeting to specific cellular compartments such as the endoplasmic reticulum or chloroplasts. The use of viral or bacterial signal peptides has been shown to enhance protein folding and stability, improving antigen yield and bioavailability. Moreover, the incorporation of molecular adjuvants and selfassembling virus-like particles (VLPs) has further enhanced the immunogenic properties of plant-derived vaccines, making them more effective in generating protective immunity.

Description

The diversity of plant-based vaccine platforms allows for the expression of a wide range of antigens, including those from viruses, bacteria, and parasites. Several plant species have been explored for vaccine production, with Nicotiana benthamiana, tobacco, lettuce, and rice being among the most commonly used hosts. Transient expression systems using Agrobacteriummediated infiltration or viral vectors have enabled rapid and high-level antigen production, allowing for quick responses to emerging infectious diseases. Additionally, stable transgenic plants offer the advantage of long-term antigen production and the potential for oral vaccine delivery through edible plant tissues. This diversity in plant-based expression systems provides flexibility in vaccine formulation and administration routes, making them suitable for different immunization strategies. Optimizing production strategies for plantbased vaccines is essential to achieve high yields, cost-effectiveness, and regulatory compliance. Advances in agroinfiltration techniques, bioreactor cultivation, and purification methods have significantly improved the scalability and efficiency of plant-based vaccine manufacturing. Agroinfiltration using engineered bacterial strains such as Agrobacterium tumefaciens enables rapid gene transfer and transient expression of antigens within plant tissues. This method allows for high-yield protein production within a short timeframe, making it ideal for pandemic response scenarios. Bioreactor-based plant cultivation, including hydroponic and aeroponic systems, further enhances biomass production and consistency, ensuring a stable supply of vaccine components. Purification strategies such as affinity chromatography, ultrafiltration, and precipitation techniques have been optimized to isolate plant-derived antigens with high purity and bioactivity, ensuring their safety and efficacy in clinical applications [1].

The advantages of plant-based vaccines extend beyond their production efficiency and diversity. One of the most significant benefits is their potential for needle-free administration through oral or mucosal routes. Edible plant vaccines, where antigens are expressed in food crops such as lettuce, tomato, or banana, offer an innovative approach to mass immunization, particularly in resource-limited settings. By consuming plant tissues containing vaccine antigens, individuals can develop immune responses without the need for refrigeration, cold-chain logistics, or trained medical personnel for administration. This approach has the potential to revolutionize vaccine distribution and accessibility, particularly in regions with limited healthcare infrastructure. Despite the many advantages of plant-based vaccines, several challenges must be addressed to fully realize their potential. Regulatory approval remains a significant hurdle, as plant-derived pharmaceuticals must meet stringent safety and efficacy standards before they can be deployed for human use. The presence of plant-specific glycans, potential allergenicity, and batch-to-batch variability are factors that require careful consideration during vaccine development and quality control. Advances in glycoengineering and recombinant protein purification have been instrumental in overcoming these challenges, ensuring that plant-derived antigens are structurally and functionally comparable to their conventionally produced counterparts [2].

Additionally, public perception and acceptance of genetically modified plant-based vaccines play a crucial role in their widespread adoption. While plant-based vaccines offer numerous advantages, concerns about genetic modification and environmental impact need to be addressed through transparent communication and regulatory oversight. Educating the public on the safety, efficacy, and sustainability of plant-based vaccines will be essential in gaining trust and ensuring their successful integration into global immunization programs. Recent advancements in plant-based vaccine research have demonstrated their potential in addressing infectious diseases such as influenza, human papillomavirus (HPV), norovirus, and even emerging pathogens like SARS-CoV-2. The rapid response capabilities of plant expression systems have been highlighted during the COVID-19 pandemic, where plant-derived vaccine candidates were developed and progressed through clinical trials in record time. The ability to rapidly produce vaccine antigens in plants without the need for large-scale bioreactors or expensive cell culture facilities positions plant-based vaccines as a viable solution for future pandemic preparedness and response [3].

Moreover, plant-based vaccines hold promise for veterinary applications, providing cost-effective immunization solutions for livestock and companion animals. The development of oral plant-based vaccines for animal diseases such as foot-and-mouth disease, avian influenza, and porcine epidemic diarrhea virus has demonstrated their efficacy in controlling infectious outbreaks while reducing the economic burden on farmers and the agricultural industry. The use of plant-based vaccine technology in veterinary medicine further underscores its versatility and potential impact on both human and animal health. The integration of plant-based vaccines into mainstream vaccine development pipelines will require continued investment in research, infrastructure, and regulatory frameworks. Collaborative efforts between academia, industry, and government agencies will be essential in advancing this technology and ensuring its widespread adoption. By leveraging the unique advantages of plant-based expression systems, researchers can develop innovative and sustainable vaccine solutions that address global health challenges in an efficient and cost-effective manner [4,5].

Conclusion

In conclusion, plant-based vaccines represent a groundbreaking approach to immunization, offering a combination of antigen design flexibility, diversity, and high-level production efficiency. Through advances in genetic engineering, expression system optimization, and scalable production techniques, plantbased vaccines have the potential to revolutionize the way vaccines are developed and distributed. While challenges remain in regulatory approval, public acceptance, and large-scale manufacturing, continued research and technological innovation will pave the way for the widespread implementation of plant-based vaccines in human and veterinary medicine.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Mason, Hugh S., D. M. Lam and Charles J. Arntzen. "Expression of hepatitis B surface antigen in transgenic plants." Proc Natl Acad Sci 89 (1992): 11745-11749.

   Google Scholar, Crossref, Indexed at

2. Zieneldien, Tarek, Janice Kim, Jessica Cao and Chuanhai Cao. "COVID-19 vaccines: Current conditions and future prospects." Biol 10 (2021): 960.

   Google Scholar, Crossref, Indexed at

3. Maharjan, Puna Maya and Sunghwa Choe. "Plant-based COVID-19 vaccines: Current status, design, and development strategies of candidate vaccines." Vaccines 9 (2021): 992.

   Google Scholar, Crossref, Indexed at

4. Chan, Hui‐Ting, Yuhong Xiao, William C. Weldon and Steven M. Oberste, et al. "Cold chain and virus‐free chloroplast‐made booster vaccine to confer immunity against different poliovirus serotypes." Plant biotechnol j 14 (2016): 2190-2200.

   Google Scholar, Crossref, Indexed at

5. Rybicki, Edward P. "Plant molecular farming of virus‐like nanoparticles as vaccines and reagents." Wiley Interdiscip Rev Nanomed Nanobiotechnology 12 (2020): e1587.

   Google Scholar, Crossref, Indexed at